<DOC>
	<DOCNO>NCT01580397</DOCNO>
	<brief_summary>Patients metastatic , locally advanced , unresectable pancreatic ductal carcinoma ( PDA ) fail prior chemotherapy gemcitabine regimens extremely poor prognosis progression-free survival around 13 week median overall survival approximately 20 week second line chemotherapy . Recent study suggest albumin may preferentially concentrate pancreatic cancer appear starve protein . Thus , molecule attach albumin would also collect inside tumor . Based postulated mechanism action , INNO-206 may improve activity doxorubicin without increase toxicity , demonstrate animal study , induce enhance anti-tumor efficacy .</brief_summary>
	<brief_title>Pilot Phase 2 Study Investigate Preliminary Efficacy Safety INNO-206 Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Age ≥ 18 year age ; male female . Histologically cytologically confirm , locally advanced , unresectable , and/or metastatic pancreatic ductal adenocarcinoma . Cancer progression treatment one gemcitabine one fluoropyrimidinecontaining chemotherapy regimen . Capable provide informed consent comply trial procedure . ECOG performance status 01 . Life expectancy ≥ 8 week . Measurable tumor lesion accord RECIST 1.1 criterion . Women must able become pregnant ( eg postmenopausal least 1 year , surgically sterile , practice adequate birth control method ) duration study . ( Adequate contraception include : oral contraception , implanted contraception , intrauterine device implant least 3 month , barrier method conjunction spermicide . ) Women child bear potential must negative serum urine pregnancy test Screening Visit nonlactating . Geographic accessibility site . Prior exposure &gt; 3 cycle 225 mg/m2 doxorubicin Doxil® . Palliative surgery and/or radiation treatment le 4 week prior Randomization . Exposure investigational agent within 30 day Randomization . Evidence central nervous system ( CNS ) metastasis ( negative imaging study , clinically indicate , within 4 week Screening Visit ) . History malignancy ( except cure basal cell carcinoma , superficial bladder cancer carcinoma situ cervix ) unless document free cancer ≥ 5 year . Laboratory value : Screening serum creatinine &gt; 1.5x upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) &gt; 3×ULN &gt; 5×ULN liver metastasis present , total bilirubin &gt; 3×ULN , absolute neutrophil count &lt; 1,500/mm3 , platelet concentration &lt; 100,000/mm3 , absolute lymphocyte count &lt; 1000/mm3 , hematocrit level &lt; 27 % female &lt; 30 % male , coagulation test ( prothrombin time [ PT ] , partial thromboplastin time [ PTT ] , International Normalized Ratio [ INR ] ) &gt; 1.5×ULN , serum albumin ≤ 2.8 g/dL . Clinically evident congestive heart failure &gt; class II New York Heart Association ( NYHA ) guideline . Current , serious , clinically significant cardiac arrhythmia , define existence absolute arrhythmia ventricular arrhythmia classify Lown III , IV V. History sign active coronary artery disease without angina pectoris . Serious myocardial dysfunction ultrasounddetermined , absolute leave ventricular ejection fraction ( LVEF ) &lt; 45 % predict . History HIV infection . Active , clinically significant serious infection require treatment antibiotic , antiviral antifungal . Major surgery within 4 week prior Randomization . Substance abuse condition might interfere subject 's participation study evaluation study result . Any condition unstable could jeopardize subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>INNO-206</keyword>
	<keyword>Doxorubicin-EMCH</keyword>
</DOC>